Risk factors for gastrointestinal adverse events in HIV treated and untreated patients

AIDS Reviews

Volumn 11, Issue 1, 2009, Pages 30-38

  Hill, Andrew ^a   Balkin, Andrew ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Ambermed Ltd   (United Kingdom)

Author keywords

Adverse events; Antiretrovirals; Boosted PI; Diarrhea; Gastrointestinal; HIV; Nausea; Toxicity; Vomiting

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT; PYRIDAZINE DERIVATIVE;

CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MONOTHERAPY; NAUSEA; NEUROTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; RASH; REVIEW; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VOMITING; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DRUG EFFECT; GASTROINTESTINAL DISEASE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PHYSIOLOGY;

CLINICAL TRIALS AS TOPIC; DIARRHEA; GASTROINTESTINAL DISEASES; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; IMMUNE TOLERANCE; PEPTIDE FRAGMENTS; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RITONAVIR; ZIDOVUDINE;

EID: 65549084011     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Norval D. Symptoms and sites of pain experienced by AIDS patients. S Afr Med J. 2004;94:450-4.
2. Thom K, Forrest G. Gastrointestinal infections in immunocompromised hosts. Curr Opin Gastroenterol. 2006;22:18-23.
3. Brenchley J, Price D, Schacker T, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12:1365-71.
4. Bernet M, Brassart D, Neeser J, Servin A. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol. 1993;59: 4121-8.
5. De Vrese M, Marteau P. Probiotics and prebiotics: effects on diarrhea. J Nutr. 2007;137:803-11S.
6. Saavedra J, Bauman N, Oung I, Perman J, Yolken R. Feeding of bifidobacterium bifidum and Streptococcs thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus. Lancet. 1994; 344:1046-9.
7. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr. 2005;40:413-21.
8. Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients. 15th CROI, February 2008, Boston, USA [abstract 790].
9. Johnson M, Campbell T, Clotet B, Katlama C, Lazzarin A, Towner W. DUET-2: Week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 591 treatmentexperienced HIV-1-infected patients. 15th CROI, February 2008, Boston, USA [abstract 791].
10. O'Brien M, Clark R, Besch C, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407-14.
11. Siddiqui U, et al. HIV-associated diarrhea in the era of HAART: Still prevalent after all these years. Digestive Disease Week, May 2003, USA [abstract S1065 (poster)].
12. Division of AIDS table for grading the severity of adult and paediatric adverse events. DAIDS 2007; http://rcc.tech.res.com/DAIDS%20RCC%20Forms/ TB_ToxicityTables_DAIDS_AE_GradingTable_Final-Dec2004.pdf (accessed March 2007).
13. Hill A, Prakash M, Moecklinghoff C. Measuring gastrointestinal adverse events in clinical trials. Presented at the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, November 2008, London, UK [abstract P89].
14. De Jesus E, McCarty D, Farthing C, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV Infection: A randomized equivalence trial. Clin Infect Dis. 2004;39:411-8.
15. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral naive HIV infected adults. Clin Infect Dis. 2004;39:1038-46.
16. Gallant J, DeJesus E, Arribas J, et al. Tenofovir DF, emtricitabine and efavirenz vs zidovudine, lamivudine and efavirenz for HIV. N Engl J Med. 2006;354:251-60.
17. Smith K, Weinberg W, DeJesus E, et al. Fosamprenavir or atazanavir with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48 week results of ALERT. AIDS Res Ther. 2008;5:5.
18. Koch M, Volberding P, Lagakos S, Booth D, Pettinelli C, Myers M. Toxic effects of zidovudine in asymptomatic HIV-infected individuals with CD4+ cell counts of 0.5 × 109/L or less. Arch Intern Med. 1992; 152: 2286-92.
19. Schooley R, Ruane P, Myers R, et al. Tenofovir DR in antiretroviral experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257-63.
20. Squires K, Pozniak A, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside resistant HIV-1 infection. Ann Intern Med. 2003;139: 313-20.
21. Smith K, Fine D, Patel P, et al. Efficacy and safety of abacavir/ lamivudine compared to tenofovir/emtricitabine in combination with one-daily lopinavir-ritonavir through 48 weeks in the HEAT Study. 15th CROI, February 2008, Boston, USA [abstract 774].
22. Saag M, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180-9.
23. Perry C, Noble S. Didanosine: an updated review of its use in HIV infection. Drugs. 1999;58:1099-135.
24. Riddler S, Haubrich R, DiRienzo A, et al. (ACTG Study 5142 Team). Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106.
25. Markowitz M, Saag M, Powderly W, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;23:1534-9.
26. Danner S, Carr A, Leonard J, et al. A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV protease. N Engl J Med. 1995;333:1528-34.
27. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002; 346:2039-46.
28. Bogovanni M, Cicconi P, Landonio S, et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents. 2005;26:88-91.
29. Johnson M, Gathe J, Pocdzamczer D, et al. A once-daily lopinavir/ ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;43:153-60.
30. Gathe J, daSilva B, Loufty M, et al. Study M05-730 primary efficacy results at week 48: Phase 3, randomized, open-label study of lopinavir-ritonavir (LPV/r) tablets once-daily versus twice-daily, co-administered with tenofovir (TDF) + emtricitabine (FTC) in antiretroviral naïve HIV-1 infected subjects. 15th CROI, February 2008, Boston, USA [abstract 775].
31. Klein C, Chiu Y, Awni W, et al. The tablet formulation of lopinavir/ ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007;44:401-10.
32. Molina J, et al. Efficacy and safety of boosted once-daily atazanavir and twice-daily lopinavir regimens in treatment-naïve HIV-1 infected subjects. CASTLE: 48-week results. 15th CROI, February 2008, Boston, USA [presentation 37].
33. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-94.
34. Smith K, et al. Once-daily ritonavir (100mg) boosting of fosamprenavir (FPV/r) or atazanavir (ATZ/r) with tenofovir (TDF)/emtricitabine (FTC) in ART-naïve HIV-infected patients: 48 week safety/efficacy results from COL103952 (ALERT). 4th International AIDS Conference, July 2007, Sydney, Australia [abstract WEPEB023].
35. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir-ritonavir in treatment naive HIV-1 infected patients at Week 48. AIDS. 2008;22:1389-97.
36. Madruga J, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled phase III trial. Lancet. 2007;370:49-58.
37. FosAmprenavir (Lexiva) US prescribing information. GlaxoSmithKline/ Vertex, May 2004 (www.lexiva.com).
38. Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-82.
39. Hicks C, De Jesus E, Wohl D, Liao Q, Pappa K, Lancaster T. Once-daily fosamprenavir boosted with either 100mg or 200mg of ritonavir along with abacavir/lamivudine: 48 week safety and efficacy results from COL100758. 11th European AIDS Conference, October 2007, Madrid, Spain [abstract PS 7.01].
40. Walmsley S, Ruxrungtham K, Slim J, et al. The Gemini Study: saquinavir/r (SQV/r) vs lopinavir (LPV/r) plus emtricitabine/tenofovir (FTC/TDF) as initial therapy in HIV-1 infected patients. 11th European AIDS Conference, October 2007, Madrid, Spain [abstract PS1/4].
41. Dragsted U, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1 infected patients: the MaxCmin 2 trial. Antivir Ther. 2005;10:735-43.
42. Hicks C, Cahn P, Cooper D, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466-75.
43. Cooper D, et al. Efficacy and safety of two doses of tipranavir/ ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naive patients: results of BI 1182.33. 8th International Congress on Drug Therapy in HIV Infection, October 2006, Glasgow [abstract PL13.4].
44. Grinzstein B, Nguyen B, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment experienced patients with multidrug resistant virus: a Phase II randomized controlled trial. Lancet. 2007;369:1261-9.
45. Cooper D, Steigbigel R, Gatell J, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359: 355-65.
46. Saag M, Ive P, Heera J, et al. A multicentre, randomised, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/ lamivudine[3TC], for the treatment of antiretroviral naive patients infected with R5 HIV1; Week 48 results of the MERIT Study. 4th IAS Conference on HIV pathogenesis, treatment and prevention, July 2007, Sydney, Australia [abstract WESS104].
47. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-41.